| Project/Area Number |
18K15330
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2021: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2020: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 腫瘍診断学 / 腫瘍治療学 / 腫瘍生物学 |
|---|
| Outline of Final Research Achievements |
We collected and analyzed 209 stage II gastric cancer specimens that received postoperative adjuvant chemotherapy at S-1.
Of the 209 cases, MSI status was evaluable in 185 samples (88.5%), and MSI-H was confirmed in 24 samples (13%). There was no significant difference between MSI-H and MSS in recurrence-free survival (RFS) [HR, 1.00; p = 0.997] and overall survival (OS) [HR, 0.66; p = 0.488], but MSI-H GCs had a better RFS than MSS [HR, 0.34; p = 0.064] and OS [HR, 0.22; p = 0.057] significantly better than MSS after adjusting for patient background with propensity scores.
|
| Academic Significance and Societal Importance of the Research Achievements |
MSI/dMMR がTS-1胃癌術後補助化学療法に与える影響についての検討はこれまでにない。また遺伝子発現によって見出された「MSI like」と真のMSIとの違いを検討した研究は他になく、学術的独自性がある。米国ではMSI/dMMRに対する抗PD-1抗体の投与がFDAによって承認されており、MSI/dMMRは胃癌における抗PD-1抗体の効果予測マーカーの候補と考えられている。MSS/pMMRの中にMSI/dMMRと類似した免疫環境の腫瘍が存在する可能性があり、これが「MSI like」である可能性を考えている。これらは免疫チェックポイント阻害剤の応用が期待でき、創造性がある。
|
